Allarity Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Allarity Therapeutics R&D Spending Growth & History (ALLR)
Allarity Therapeutics's r&d spending was $6.6M for fiscal 2025.
View full Allarity Therapeutics company overviewAllarity Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.6M | $505,000 | +8.28% |
| 2024 | 2024-12-31 | $6.1M | −$1.0M | −14.18% |
| 2023 | 2023-12-31 | $7.1M | $173,000 | +2.50% |
| 2022 | 2022-12-31 | $6.9M | −$7.3M | −51.18% |
| 2021 | 2021-12-31 | $14.2M | $10.0M | +236.56% |
| 2020 | 2020-12-31 | $4.2M | — | — |
Allarity Therapeutics quarterly r&d spending
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.3M | −$976,000 | −42.05% |
| Q1 2026 | 2026-03-31 | $1.3M | −$106,000 | −7.56% |
| Q4 2025 | 2025-12-31 | $1.7M | −$173,000 | −9.37% |
| Q3 2025 | 2025-09-30 | $1.2M | $182,000 | +17.83% |
| Q2 2025 | 2025-06-30 | $2.3M | $1.3M | +119.38% |
| Q1 2025 | 2025-03-31 | $1.4M | −$767,000 | −35.35% |
| Q4 2024 | 2024-12-31 | $1.8M | −$776,000 | −29.58% |
| Q3 2024 | 2024-09-30 | $1.0M | −$927,000 | −47.59% |
| Q2 2024 | 2024-06-30 | $1.1M | −$47,000 | −4.25% |
| Q1 2024 | 2024-03-31 | $2.2M | $743,000 | +52.07% |
| Q4 2023 | 2023-12-31 | $2.6M | $1.7M | +178.75% |
| Q3 2023 | 2023-09-30 | $1.9M | −$1.1M | −35.15% |
| Q2 2023 | 2023-06-30 | $1.1M | −$591,000 | −34.85% |
| Q1 2023 | 2023-03-31 | $1.4M | $138,000 | +10.71% |
| Q4 2022 | 2022-12-31 | $941,000 | −$8.4M | −89.89% |
| Q3 2022 | 2022-09-30 | $3.0M | $1.6M | +121.70% |
| Q2 2022 | 2022-06-30 | $1.7M | −$583,000 | −25.58% |
| Q1 2022 | 2022-03-31 | $1.3M | $38,000 | +3.04% |
| Q4 2021 | 2021-12-31 | $9.3M | — | — |
| Q3 2021 | 2021-09-30 | $1.4M | $570,000 | +72.61% |
| Q2 2021 | 2021-06-30 | $2.3M | — | — |
| Q1 2021 | 2021-03-31 | $1.3M | — | — |
| Q3 2020 | 2020-09-30 | $785,000 | — | — |
Allarity Therapeutics r&d spending trends
Over the last five fiscal years, Allarity Therapeutics's r&d spending increased from $4.2M to $6.6M, a change of $2.4M. The latest reported quarter, Q2 2026, shows $1.3M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Allarity Therapeutics source filings ↗